The largest database of trusted experimental protocols

Dako link platform

Manufactured by Agilent Technologies
Sourced in Spain, Germany

The Dako Link platform is a laboratory equipment designed for automated immunohistochemistry and in situ hybridization. It provides a standardized and consistent workflow for tissue-based analysis.

Automatically generated - may contain errors

2 protocols using dako link platform

1

Immunohistochemical Analysis of Tumor Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
FFPE 3-µm sections were obtained from paraffin-embedded human tumor xenografts in mice and human tumors, and IHC was performed as previously described [50 (link)]. Briefly, FFPE sections were placed on positively charged glass slides on a Dako Link platform (Dako, Agilent Technologies Spain, Madrid, Spain). After deparaffinization, heat antigen retrieval was performed in a pH 9 EDTA-based buffered solution (Dako). Endogenous peroxidase was quenched. Primary antibodies (all from Cell Signaling) against YAP1 (#14074), TAZ (#1674883/v386), cleaved caspase3 (c-casp3) (1:100), and phospho-Histone3-Ser10 (pH3) (1:100) were used, and HER2 status was assessed by HercepTest (K5207; Dako). Antigen–antibody reaction was detected by incubation with an anti-mouse/rabbit Ig-dextran polymer coupled with peroxidase (Flex+, Dako). Sections were then visualized with 3,3′-diaminobenzidine and counterstained with hematoxylin. All immunohistochemical staining was performed on a Dako Autostainer platform. A semiquantitative estimation of the percentage of tumor cells positively stained for YAP1 and TAZ nuclear expression was calculated by a pathologist (FR), and the results ranged from 0 to 100. Proper positive and negative controls were assayed to validate the staining procedure (Figure S16).
+ Open protocol
+ Expand
2

PD-L1 Protein Expression Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
When tumor material of an appropriate quality and quantity was available, PD-L1 protein expression (expression in tumor cells) was assessed by using immunohistochemistry with a ready-to-use PD-L1 commercial kit (HalioSeek, Halkio Dx, National Harbor, Maryland) or with QR1 antibody (Quartet, Quartett Immunodiagnosika & Biotechnologie GmBH, Berlin, Germany) on a Dako Link platform (Dako, Glostrop, Denmark), at the pathology platforms of Marseille and Toulouse, respectively.
The percentage of tumor cells positive for PD-L1 protein expression was reported. Furthermore, the positivity of the tumors for PD-L1 expression was considered for two thresholds currently used in clinical practice: 1% or more and 50% or more positive tumor cells. 8
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!